Proteasome Substrate III Fluorogenic Catalog number: B2014186 Lot number: Batch Dependent Expiration Date: Batch dependent Amount: 2.5 mg Molecular Weight or Concentration: 763.8 g/mol Supplied as: Powder Applications: molecular tool for various biochemical applications Storage: -20°C Keywords: Proteasome Substrate III, Fluorogenic, Suc-LLVY-AMC, Chymotrypsin Substrate III, Fluorogenic Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. References Nehybov T, marda J, Daniel L, Stiborek M, Kanick_ V, Spasojevi I, Preisler J, Damborsk_ J, Bene P. Wedelolactone Acts as Proteasome Inhibitor in Breast Cancer Cells Int J Mol Sci. 2017 Mar 29;18(4):729. Morales P, Kong M, Pizarro E, Pasten C. Participation of the sperm proteasome in human fertilization Hum Reprod. 2003 May;18(5):1010-7. Sixt SU, Costabel U, Bonella F, Grunert K, Alami R, Hakenbeck J, Bauer P, Dahlmann B, Schmid KW, Peters J, Wohlschlaeger J. Alveolar and intraparenchymal proteasome in sarcoidosis Respir Med. 2014 Oct;108(10):1534-41. Gohlke S, Kloss A, Tsokos M, Textoris-Taube K, Keller C, Kloetzel PM, Dahlmann B. Adult human liver contains intermediate-type proteasomes with different enzymatic properties Ann Hepatol. 2014 Jul-Aug;13(4):429-38. Ottenheijm CA, Heunks LM, Li YP, Jin B, Minnaard R, van Hees HW, Dekhuijzen PN. Activation of the ubiquitin-proteasome pathway in the diaphragm in chronic obstructive pulmonary disease Am J Respir Crit Care Med. 2006 Nov 1;174(9):997-1002. Dahlmann B, Ruppert T, Kloetzel PM, Kuehn L. Subtypes of 20S proteasomes from skeletal muscle Biochimie. 2001 Mar-Apr;83(3-4):295-9. Baldovino S, Piccinini M, Anselmino A, Ramondetti C, Rinaudo MT, Costanzo P, Sena LM, Roccatello D. Structural and functional properties of proteasomes purified from the human kidney J Nephrol. 2006 Nov-Dec;19(6):710-6. Hassan SB, Lvborg H, Lindhagen E, Karlsson MO, Larsson R. CHS 828 kill tumour cells by inhibiting the nuclear factor-kappaB translocation but unlikely through down-regulation of proteasome Anticancer Res. 2006 Nov-Dec;26(6B):4431-6. Pahler JC, Ruiz S, Niemer I, Calvert LR, Andreeff M, Keating M, Faderl S, McConkey DJ. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia Clin Cancer Res. 2003 Oct 1;9(12):4570-7.
